Jupiter Life Line Hospitals has secured an 80‑year lease for a 10,026‑square‑metre plot in Mumbai’s Bandra-Kurla Complex (BKC) with a winning bid of Rs 354 crore, the company said on March 27.
The lease awarded by the Mumbai Metropolitan Region Development Authority (MMRDA) will allow the healthcare provider to set up a 400-bed facility in the city’s premier business district.
The facility, which will be Jupiter’s seventh hospital and first in BKC, will take its total bed capacity to about 3,000, joint managing director and CEO Ankit Thakker said.
“BKC is amongst the most important locations of the country,” Thakker said, describing the proposed hospital as a “fitting addition” to Mumbai’s healthcare ecosystem and aligned with the government’s Heal in India medical‑tourism push.
The move places Jupiter among a small group of hospital operators willing to commit large amounts of capital to long‑gestation projects in premium real estate corridors, where land scarcity and costs often deter all but the largest players.
For Jupiter, the transaction strengthens its presence in high‑growth western India while embedding the brand in one of the city’s most valuable commercial districts.
The Rs 354‑crore payment represents only the land cost. Capital expenditure for construction, clinical equipment, interiors and commissioning will be incremental and has not been quantified by the company.
On a land‑only basis, the deal implies an upfront cost of roughly Rs 0.9 crore per planned bed — before factoring in build and operating expenses.
The BKC hospital fits into a broader expansion plan. Jupiter is investing nearly Rs 1,400 crore to double capacity over the next few years, as demand for high‑quality tertiary care rises in dense but underserved urban clusters.
The company operates 1,061 beds and is targeting 2,500 beds over the next four years, excluding the proposed BKC hospital.
Three new hospitals are already under development — in Dombivli and Mira‑Bhayandar in the Mumbai Metropolitan Region and in Pune’s Bibwewadi — reinforcing Jupiter’s focus on Maharashtra as its core growth geography.
Unlike peers that have leaned heavily on private equity‑fuelled roll‑ups and asset‑light models, Jupiter has pursued a more contrarian strategy centred on long‑term, greenfield hospital projects.
The company typically spends more than three years identifying land parcels, navigating regulatory approvals, constructing facilities and building clinical teams before opening doors to patients.
That approach is capital‑intensive but offers greater control over clinical outcomes and long‑term returns, a trade‑off Jupiter appears increasingly comfortable making.
Financially, the company enters its next expansion cycle with a relatively strong balance sheet.
Jupiter reported a closing cash balance of about Rs 724 crore as of December 31, 2025, alongside consolidated gross debt of roughly Rs 325–340 crore.
Revenue for the first nine months of FY26 stood at Rs 1,030 crore, with net profit of Rs 127 crore.
The BKC bet underscores management’s confidence in sustained utilisation and pricing power in premium urban locations, even as competition intensifies across India’s private healthcare landscape. It also signals a willingness to absorb near‑term capital strain in exchange for long‑duration assets in irreplaceable locations.